James T. Milnes

Atrial‐like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial‐selective pharmacology

Harsha D. Devalla, Verena Schwach, John W. Ford et al. · EMBO Molecular Medicine · 2015 · 367 citations · Full text

Cardiac Muscle, Medicine, Atrial‐selective Pharmacology +7

Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652

James T. Milnes, Olivia Crociani, Annarosa Arcangeli et al. · British Journal of Pharmacology · 2003 · 175 citations · Full text

Neurotransmitter, Molecular Biology, Cellular Pharmacology +23

The N588K-HERG K+ channel mutation in the ‘short QT syndrome’: Mechanism of gain-in-function determined at 37 °C

Mark J. McPate, Rona S. Duncan, James T. Milnes et al. · Biochemical and Biophysical Research Communications · 2005 · 127 citations

Channelopathies, Signal Transduction, Mendelian Disorder +6

The Low-Potency, Voltage-Dependent HERG Blocker Propafenone—Molecular Determinants and Drug Trapping

Harry J. Witchel, Christopher E. Dempsey, Richard B. Sessions et al. · Molecular Pharmacology · 2004 · 103 citations

Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 °C: Cisapride versus dofetilide

James T. Milnes, Harry J. Witchel, Joanne L. Leaney et al. · Journal of Pharmacological and Toxicological Methods · 2010 · 96 citations